KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBT Margin: 2011-2025

Historic EBT Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Sep 2025 value amounting to -30.17%.

  • Supernus Pharmaceuticals' EBT Margin fell 5575.00% to -30.17% in Q3 2025 from the same period last year, while for Sep 2025 it was -3.04%, marking a year-over-year decrease of 1416.00%. This contributed to the annual value of 14.79% for FY2024, which is 1433.00% up from last year.
  • Supernus Pharmaceuticals' EBT Margin amounted to -30.17% in Q3 2025, which was down 399.44% from 10.07% recorded in Q2 2025.
  • Supernus Pharmaceuticals' EBT Margin's 5-year high stood at 25.58% during Q3 2024, with a 5-year trough of -30.17% in Q3 2025.
  • Over the past 3 years, Supernus Pharmaceuticals' median EBT Margin value was 5.86% (recorded in 2023), while the average stood at 2.98%.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 2,826bps in 2024, then slumped by 5,575bps in 2025.
  • Supernus Pharmaceuticals' EBT Margin (Quarterly) stood at 1.29% in 2021, then soared by 1,971bps to 21.00% in 2022, then crashed by 2,040bps to 0.60% in 2023, then skyrocketed by 1,455bps to 15.15% in 2024, then crashed by 5,575bps to -30.17% in 2025.
  • Its EBT Margin was -30.17% in Q3 2025, compared to 10.07% in Q2 2025 and -3.89% in Q1 2025.